The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $10.73 in the last session, down -2.37% from day before closing price of $10.99. In other words, the price has decreased by -$2.37 from its previous closing price. On the day, 3.75 million shares were traded. NTLA stock price reached its highest trading level at $11.1 during the session, while it also had its lowest trading level at $10.71.
Ratios:
We take a closer look at NTLA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.19 and its Current Ratio is at 5.19. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.11.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 23 ’25 when Dulac Edward J III sold 7,462 shares for $14.02 per share. The transaction valued at 104,617 led to the insider holds 106,062 shares of the business.
Clark Eliana sold 1,022 shares of NTLA for $10,036 on Jul 01 ’25. The EVP, Chief Technical Officer now owns 95,369 shares after completing the transaction at $9.82 per share. On Jul 02 ’25, another insider, Dube Michael P, who serves as the VP, Chief Accounting Officer of the company, sold 2,503 shares for $9.95 each. As a result, the insider received 24,905 and left with 57,137 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1151833216 and an Enterprise Value of 794772096. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.79 while its Price-to-Book (P/B) ratio in mrq is 1.58. Its current Enterprise Value per Revenue stands at 15.036 whereas that against EBITDA is -1.584.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.28, which has changed by -0.5371009 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $24.16, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -1.07%, while the 200-Day Moving Average is calculated to be 0.40%.
Shares Statistics:
According to the various share statistics, NTLA traded on average about 5.16M shares per day over the past 3-months and 4967670 shares per day over the past 10 days. A total of 105.33M shares are outstanding, with a floating share count of 101.22M. Insiders hold about 5.71% of the company’s shares, while institutions hold 87.30% stake in the company. Shares short for NTLA as of 1753920000 were 29708601 with a Short Ratio of 5.76, compared to 1751241600 on 30130358. Therefore, it implies a Short% of Shares Outstanding of 29708601 and a Short% of Float of 31.350002.
Earnings Estimates
Its stock is currently analyzed by 22.0 different market analysts. The consensus estimate for the next quarter is -$0.98, with high estimates of $0.04 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$2.67 and -$4.74 for the fiscal current year, implying an average EPS of -$4.11. EPS for the following year is -$3.85, with 26.0 analysts recommending between -$1.1 and -$5.05.
Revenue Estimates
A total of 26 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $30.87M, resulting in an average revenue estimate of $60.91M. In the same quarter a year ago, actual revenue was $57.88M
